21st Century Treatments for Sustainable Elimination of Leishmaniasis (360G-Wellcome-212346_Z_18_Z)
This programme will utilise innovative bi- and multilateral partnerships with pharmaceutical companies to translate recent scientific innovations into twenty-first century treatments for leishmaniasis. The treatments, combinations of highly-effective, orally-active drugs, are projected to achieve Sustainable Elimination of visceral leishmaniasis (VL) disease in Asia and Disease Control in Africa and Latin America as well as Control of cutaneous leishmaniasis (CL). The programme supports the WHO VL Elimination framework that identifies building partnerships, and clinical and operational research as three of the five key strategies for achieving Elimination goals, and WHO’s objective of detection and treatment of CL patients.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Region | International |
| Award Date | 2018-09-30T00:00:00+00:00 |
| Internal ID | 212346/Z/18/Z |
| Planned Dates: End Date | 2022-03-24T00:00:00+00:00 |
| Planned Dates: Start Date | 2019-01-25T00:00:00+00:00 |
| Amount Awarded | 10044443.99 |
| Financial Year | 2017/18 |
| Lead Applicant | Dr Charles E (Charlie) Mowbray |
| Grant Programme: Title | Innovations Priority Project |
| Applicant Surname | Mowbray |
| Approval Committee | Science, Innovation and Translation Programme Advisory Group |
| Other Applicant(s) | Dr Fabiana Alves, Dr Stephen J Robinson, Dr Jean-Yves Andre Gillon |
| Recipient Org: Country | Switzerland |
| Recipient Org: City | Geneva |
| Has the grant transferred? | No |
| Research conducted at multiple locations? | No |
| Total amount including partnership funding | 10044443.99 |